The completion of the first procedure marks the beginning of a controlled US commercial release.
Related to this article
Butterfly Medical has also submitted a premarket approval application to the FDA.
Rezūm improved symptoms and quality of life at 1 year vs combination pharmacotherapy in sexually active men with BPO while preserving sexual function.
Advertisement
Advertisement
Trending on Urology Times
1
PROTEUS Substudy: Perioperative apalutamide plus ADT improves EFS vs surgery alone
2
European Commission approves perioperative pembrolizumab plus enfortumab vedotin for MIBC
3
FDA accepts new drug application for UGN-103 in recurrent LG-IR-NMIBC
4
How PSMA-PET shapes staging and recurrence workup in prostate cancer
5